Aptevo Therapeutics Inc. — Form 8-K
Filed September 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aptevo reported that 13 of 14 evaluable TP53-mutated frontline AML patients treated with mipletamig triplet (mipletamig + venetoclax + azacitidine) achieved clinical benefit; 11 (79%) achieved CR/CRi, nearly double the 41% published remission rate for venetoclax/azacitidine alone. RAINIER Phase 1b/2 trial expected to complete by year-end 2026 with regulatory interaction planned for 1H27.
Why this rating
Early-stage clinical results in lead candidate represent material progress for a $9.8M biotech. Favorable TP53-mutated AML data supports next-phase trial progression, addressing orphan indication. However, Phase 1b data with small patient cohort (n=14) carries execution risk; regulatory and Phase 2 outcomes uncertain.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $2.15 ▼ 17.30% | at our read · unknown $2.60 | +10 min · unknown $2.60 ▲ 0.00% | +30 min · unknown $2.60 ▲ 0.00% | +1 hr · unknown $2.60 ▲ 0.00% | +4 hrs pending |
The stock had already moved +20.92% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.